Document:

Exhibit

Exhibit 10.4

AMENDMENT NO. 2 TO THE   
AIR PRODUCTS AND CHEMICALS, INC. 
RETIREMENT SAVINGS PLAN

WHEREAS, Air Products and Chemicals, Inc. (the “Company”) is the Plan Sponsor of the Air Products and Chemicals, Inc. Retirement Savings Plan (the “Plan”); and
WHEREAS, pursuant to Plan Section 7.01 the Plan may be amended at anytime; and
WHEREAS, the Plan Year is the period beginning on October 1 and ending on September 30 of the following calendar year; and
WHEREAS, the Company desires to amend the Plan to change the Plan Year from October 1 to September 30 to January 1 to December 31 and in connection with such amendment will deem the period beginning on October 1, 2018 and ending on December 31, 2018 to be a Short Plan Year.
NOW, THEREFORE, the Plan is hereby amended as follows:

		
	1.
	Effective January 1, 2019, Section 2.49 shall be amended to read as follows:

“2.49 Plan Year means the annual period beginning on January 1 and ending on December 31 of the calendar year.  A Plan Year shall also be the limitation year for purposes of applying the limitations of Code Section 415.  For purposes of this section, the period beginning on October 1, 2018 and ending on December 31, 2018 shall be a short Plan Year.”

		
	2.
	In all other respects the Plan shall remain in full force and effect.

IN WITNESS WHEREOF, the Company has caused its Senior Vice President Chief Human Resources Officer to execute this Second Amendment to the Plan on this ________________ day of December 2018.

AIR PRODUCTS AND CHEMICALS, INC.

By: ________________________________     
       Senior Vice President Chief  Human Resources OfficerExhibit

Exhibit 10.5

AMENDMENT NO. 3 TO THE   
AIR PRODUCTS AND CHEMICALS, INC. 
RETIREMENT SAVINGS PLAN

WHEREAS, Air Products and Chemicals, Inc. (the “Company”) is the Plan Sponsor of the Air Products and Chemicals, Inc. Retirement Savings Plan (the “Plan”); and
WHEREAS, pursuant to Plan Section 7.01 the Plan may be amended at any time; and
WHEREAS, the Bipartisan Budget Act of 2018 made several changes to the hardship withdrawal rules; and
WHEREAS, the Company desires to amend the Plan to change the Plan’s hardship withdrawal rules to (1) remove the six-month suspension of elective deferrals after receipt of a hardship withdrawal and (2) permit hardship withdrawal without regard to whether a participant has first obtained available plan loans and (3) allow distributions of qualified elective contributions, qualified matching contributions and earnings on such elective contributions.
NOW, THEREFORE, the Plan is hereby amended as follows:

		
	1.
	Effective January 1, 2019, Section 3.08(b) (iii)(B) shall be amended to read as follows:

“(B) the Participant has obtained all distributions, other than hardship distributions.  To be eligible for a hardship distribution, a Participant is not required to take a plan loan from any plan maintained by the Company or an Affiliated Company.”

		
	2.
	Effective January 1, 2019, Section 3.08(b)(iii)(C) shall be deleted.

		
	3.
	In all other respects the Plan shall remain in full force and effect.

IN WITNESS WHEREOF, the Company has caused its Senior Vice President Chief Human Resources Officer to execute this Third Amendment to the Plan on this ________________ day of December 2018.

AIR PRODUCTS AND CHEMICALS, INC.

By: ________________________________     
       Senior Vice President Chief Human Resources OfficerEX-4.1

 Exhibit 4.1 

EXECUTION VERSION 
  
 

 

DATED                       
             2018 
 MEREO BIOPHARMA GROUP PLC 

 
  

WARRANT INSTRUMENT 

relating to the issue of warrants entitling the holders to 

subscribe for Warrant Shares in the capital of 

MEREO BIOPHARMA GROUP PLC 
  

 

  
 5 Fleet Place London EC4M
7RD 
 Tel: +44 (0)20 7203 5000 • Fax: +44 (0)20 7203 0200 • DX: 19 London/Chancery Lane 

www.charlesrussellspeechlys.com 

 CONTENTS 
  

							
	 1
	    	 DEFINITIONS AND INTERPRETATION
	  	 	2	 
			
	 2
	    	 CONSTITUTION AND FORM OF WARRANTS
	  	 	8	 
			
	 3
	    	 CALCULATION OF NUMBER OF WARRANT SHARES
	  	 	9	 
			
	 4
	    	 CERTIFICATES
	  	 	9	 
			
	 5
	    	 TIMING FOR EXERCISE OF SUBSCRIPTION RIGHTS
	  	 	9	 
			
	 6
	    	 EXERCISE OF SUBSCRIPTION RIGHTS
	  	 	9	 
			
	 7
	    	 AUTOMATIC EXERCISE OF SUBSCRIPTION RIGHTS
	  	 	11	 
			
	 8
	    	 COMPLETION
	  	 	12	 
			
	 9
	    	 TRANSFER OF WARRANTS
	  	 	13	 
			
	 10
	    	 MODIFICATION AND CESSATION OF RIGHTS
	  	 	13	 
			
	 11
	    	 ADJUSTMENT OF WARRANT
	  	 	13	 
			
	 12
	    	 LIQUIDATION
	  	 	14	 
			
	 13
	    	 TAKEOVERS
	  	 	14	 
			
	 14
	    	 COMPANY REORGANISATIONS – EXCHANGE OF WARRANTS
	  	 	16	 
			
	 15
	    	 INFORMATION AND RIGHTS OF WARRANTHOLDER(S)
	  	 	16	 
			
	 16
	    	 RESTRICTIONS ON AND UNDERTAKINGS OF THE COMPANY
	  	 	17	 
			
	 17
	    	 WARRANTIES
	  	 	17	 
			
	 18
	    	 NOTICES
	  	 	18	 
			
	 19
	    	 COSTS AND EXPENSES
	  	 	18	 
			
	 20
	    	 CONTRACTS (RIGHTS OF THIRD PARTIES) ACT 1999
	  	 	18	 
			
	 21
	    	 FURTHER ASSURANCE
	  	 	19	 
			
	 22
	    	 SEVERABILITY
	  	 	19	 
			
	 23
	    	 GOVERNING LAW
	  	 	19	 
		
	 SCHEDULE 1 FORM OF WARRANT CERTIFICATE
	  	 	20	 
		
	 SCHEDULE 2 CONDITIONS
	  	 	23	 

 THIS WARRANT INSTRUMENT is made
on                2018 
 BY: 

 

	(1)	 MEREO BIOPHARMA GROUP PLC, a company incorporated in England and Wales with number 09481161 whose
registered office is at 4th Floor, 1 Cavendish Place, London, England, W1G 0QF (“Company”). 

 BACKGROUND: 

 

	(A)	 The Company, by resolution of its directors, has agreed to issue Warrants to subscribe for Warrant Shares in
the capital of the Company on the terms set out in this instrument, subject to adjustment as set out in this instrument. 

  

	(B)	 Either all of the registered holders of shares in the Company have irrevocably waived all pre-emption rights conferred on them (whether by the Companies Act, the Articles or otherwise) or such pre-emption rights have been validly disapplied in relation to the
number of Warrants and shares in the Company issued pursuant to this instrument. 

  

	(C)	 This instrument has been executed by the Company as a deed in favour of the Warrantholder.

 IT IS AGREED: 
  

	1	 DEFINITIONS AND INTERPRETATION  

 

	1.1	 In this instrument the following words and expressions shall (unless the context requires otherwise) have the
following meanings: 

  

					
		 	Adjustment	  	means any or all of the following, at any time, after issue of the relevant Warrant, or by reference to any record date, while the Warrants remain exercisable:
			
		 		  	 (a)    any allotment or issue of Equity Securities by the Company by way
of capitalisation of profits or reserves;

			
		 		  	 (b)    any cancellation, purchase or redemption of Equity Securities, or
any reduction or repayment of Equity Securities, by the Company;

			
		 		  	 (c)    any sub-division or
consolidation of Equity Securities by the Company; and

			
		 		  	 (d)    any issue of securities or other instruments convertible into
shares in, or Equity Securities of, the Company or any grant of options, warrants or other rights to subscribe for, or call for the allotment or issue of, shares in, or Equity Securities of, the
Company,

  
 2 

					
			
		 		  	but excluding any issue of Equity Securities of the Company pursuant to (i) the exercise of any options granted to employees, consultants or directors of the Company, or (ii) the loan notes in the Company currently held by
Novartis Pharma AG pursuant to a convertible loan note instrument dated 3 June 2016, as amended;
			
		 	AIM	  	the AIM market operated by the London Stock Exchange;
			
		 	AIM Rules	  	the AIM Rules for Companies published by the London Stock Exchange;
			
		 	Articles	  	the articles of association of the Company for the time being;
			
		 	Auditors	  	the Company’s auditors;
			
		 	Business	  	means the research, development, production, trading and licensing of rights, intellectual property and/or products within the life sciences industry (or any of the foregoing or any activities connected thereto);
			
		 	Business Day	  	a day (which for these purposes ends at 5.30 pm) on which banks are open for commercial business in the City of London other than a Saturday or Sunday;
			
		 	Companies Act	  	the Companies Act 2006;
			
		 	Competitor	  	means any entity (other than a reputable financial institution) whose business directly competes with the Business carried out by a Group Company;
			
		 	Conditions	  	the terms and conditions set out in Schedule 2 (subject to any alterations made in accordance with the provisions of this instrument);

  
 3 

					
		 	Consent	  	either:
			
		 		  	 (a)    a resolution passed at a meeting of the Warrantholders duly
convened and held and carried by a majority consisting of not less than 75 per cent. of the votes cast upon a show of hands or, if a poll is duly demanded, by a majority consisting of not less than 75 per cent of the votes cast on a poll;
or

			
		 		  	 (b)    the consent in writing of Warrantholders entitled to the right to
subscribe for at least 75 per cent of the Warrant Shares in respect of which Subscription Rights are granted pursuant to this instrument;

			
		 	CREST	  	the system of paperless settlement of trades and the holding of uncertificated shares administered by Euroclear UK & Ireland Limited or any other relevant paperless settlement system used in relation to the holding of
uncertificated shares in the Company;
			
		 	Directors	  	the board of directors of the Company (and/or, where relevant, a Group Company) for the time being;
			
		 	Equity Securities	  	has the meaning given in section 560(1) of the Companies Act;
			
		 	Exercise Date	  	the date of delivery to the registered office of the Company of the items specified in clause 6.2 (and the date of such delivery shall be the date on which such items are received at the Company’s registered office);
			
		 	Fair Market Value	  	either:
			
		 		  	 (a)    if the Ordinary Shares are then traded on a Recognised Investment
Exchange the fair market value of a Warrant Share shall be the volume weighted average price of one (1) Ordinary Share during the ten (10) consecutive trading day period immediately preceding the Exercise Date; or

			
		 		  	 (b)    if the Ordinary Shares are not traded on a Recognised Investment
Exchange, the fair market value a Warrant Share shall be the Fair Price;

  
 4 

					
		 	Fair Price	  	unless otherwise agreed by the board of Directors and the Warrantholder(s) prior to service of the Notice of Subscription, the price per Warrant Share which the Auditors (acting as an expert (the Expert)) shall certify to be
in its opinion a fair price for the Warrant Shares. In arriving at his opinion the Expert will value the Warrant Shares as at the date the Notice of Subscription is to be given on the basis that the Company operates as a going concern, as between a
willing seller and a willing buyer, subject always to the provisions of the Articles. The decision of the Expert as to the fair price for the Warrant Shares shall be final and binding and his costs shall be borne by the Company;
			
		 	Final Date	  	subject to clause 5 (Timing for exercise of Subscription Rights), 10 years from the date of this instrument;
			
		 	London Stock Exchange	  	London Stock Exchange plc;
			
		 	Group	  	(i) the Company and its subsidiaries (if any), (ii) any holding company of the Company, and (iii) any subsidiaries of such holding companies from time to time and Group Company means any member of the Group;
			
		 	Market Abuse Regulation	  	Market Abuse Regulation (Regulation 596/2014/EU);
			
		 	Marketable Securities	  	means securities in the acquiring entity traded on a Recognised Investment Exchange where the Warrantolder(s) (were it to receive such securities on completion of an Offer having exercised this Warrant) would not be subject to any
restrictions on re-sale of such securities;
			
		 	Member of the same Fund Group	  	is if the Warrantholder is a fund, partnership, company, syndicate or other entity whose business is managed by a Fund Manager (an “Investment Fund”) or a nominee of that person:
			
		 		  	 (a)    any participant or partner in or member of any such Investment Fund
or the holders of any unit trust which is a participant or partner in or member of any Investment Fund but only in connection with the dissolution of Investment Fund or any distribution of assets of the Investment Fund pursuant to the operation of
the Investment Fund in the ordinary course of business,

  
 5 

					
		 		  	 (b)    any Investment Fund managed or exclusively advised by that Fund
Manager,

			
		 		  	 (c)    a parent undertaking or subsidiary undertaking of that Investment
Fund or Fund Manager, or any subsidiary undertaking of any parent undertaking of that Investment Fund or Fund Manager, or

			
		 		  	 (d)    any trustee, nominee or custodian of such Investment Fund and vice
versa;

			
		 	Notice of Subscription	  	the notice addressed to the Company by a Warrantholder exercising its Subscription Rights in the form, or substantially in the form, set out in the schedule to the Warrant Certificate;
			
		 	Ordinary Shares	  	ordinary shares in the capital of the Company and having the rights and privileges set out in the Articles;
			
		 	Permitted Transferee	  	are:
			
		 		  	 (a)    a nominee of the Warrantholders;

			
		 		  	 (b)    a regulated, reputable financial institution;

			
		 		  	 (c)    a member of the SVB Financial Group of companies;
and/or

			
		 		  	 (d)    a Member of the same Fund Group;

			
		 	Recognised Investment Exchange	  	a recognised investment exchange or overseas investment exchange (within the meaning thereof given for the purposes of section 285 of the Financial Services and Markets Act 2000, and shall include, without limitation, AIM or
NASDAQ;
			
		 	Register	  	the register of persons for the time being entitled to the benefit of the Warrants to be maintained pursuant to the Conditions;
			
		 	Registrars	  	the registrars of the Company for the time being;
			
		 	Subscription Price	  	the subscription price per Warrant Share, such price being equal to £                ;
			
		 	Subscription Rights	  	the rights of the Warrantholder(s) to subscribe for Warrant Shares under clause 6 (Exercise of Subscription Rights);

  
 6 

					
		  	Takeover Code	  	the UK City Code on Takeovers and Mergers (as amended from time to time);
			
	 	  	UKLA	  	the United Kingdom Listing Authority;
			
		  	Warrant Certificate	  	a certificate evidencing a Warrantholder’s entitlement to Warrants in the form set out in Schedule 1;
			
		  	Warrant Shares	  	Ordinary Shares to be issued pursuant to the terms of the Warrants;
			
		  	Warrantholder	  	in relation to a Warrant, the person whose name appears in the Register as the holder of the Warrant; and
			
		  	Warrants	  	the warrants of the Company constituted by this instrument and all rights conferred by it (including the Subscription Rights).

 

	1.2	 In this instrument, unless the context otherwise requires: 

 

	 	1.2.1	 words and expressions defined in the Companies Act or the Articles shall have the same meanings in this
instrument (unless otherwise expressly defined in this instrument); 

  

	 	1.2.2	 headings are used for convenience only and shall be ignored in interpreting this instrument;

  

	 	1.2.3	 reference to a clause or schedule is a reference to a clause of, or schedule to, this instrument;

  

	 	1.2.4	 reference to (or to any specific provision of) this instrument or any other document or instrument shall be
construed as a reference to this instrument, that provision or that document or instrument as in force for the time being and as amended from time to time in accordance with its terms and the prior sanction of a Consent (where consent is required by
the terms of this instrument as a condition to such amendment being made); 

  

	 	1.2.5	 reference to any gender includes all genders, references to the singular includes the plural (and vice versa)
and reference to persons includes bodies corporate, unincorporated associations and partnerships (whether or not any of the same have a separate legal personality); 

 

	 	1.2.6	 reference to a statutory provision includes reference to: 

 

	 	(a)	 the statute or statutory provision as modified or re-enacted from time
to time; and 

  

	 	(b)	 any subordinate legislation made under the statutory provision (as modified or
re-enacted as set out in clause 1.2.6(a) above); 

  
 7 

	 	1.2.7	 any words following the terms ‘including’, ‘include’, ‘in particular’, ‘for
example’ or any other similar expression shall be construed as illustrative and shall not limit the sense of the words, description, phrase or term preceding those words; and 

 

	 	1.2.8	 references to statutory obligations include obligations arising under articles of the Treaty establishing the
European Community, and regulations, directives and decisions of the European Union as well as United Kingdom Acts of Parliament and subordinate legislation. 

  

	1.3	 Unless otherwise specifically provided, where any notice, resolution or document is required by this instrument
to be signed by any person, the reproduction of the signature of such person by fax or email shall suffice, provided that confirmation by first class letter is despatched by close of business on the next following Business Day, in which case the
effective notice, resolution or document shall be that sent by fax or email (served in accordance with paragraphs 11 and 12 of Schedule 2), not the confirmatory letter. 

 

	1.4	 This instrument incorporates the schedules to it. 

 

	2	 CONSTITUTION AND FORM OF WARRANTS 

 

	2.1	 This instrument constitutes the Warrants, which in aggregate give the Warrantholder(s) the right, upon the
terms and subject to the conditions set out in this instrument, to subscribe in cash (subject to clause 6.3.2) at a price per share equal to the Subscription Price for such number of Warrant Shares calculated in accordance with clause 3
(Calculation of number of Warrant Shares). 

  

	2.2	 Subject to clause 6.3.2 (Exercise of Subscription Rights), each Warrantholder shall be entitled to
subscribe in cash at the Subscription Price for that number of Warrant Shares in respect of which it is entitled to be recorded as the holder in the Register on the terms set out in this instrument. 

 

	2.3	 The Warrants shall be in registered form. 

 

	2.4	 The Warrants are issued subject to the Articles and otherwise on the terms of this instrument (including the
Conditions). 

  

	2.5	 The Company agrees with the Warrantholder(s) and, in consideration of being issued a Warrant Certificate, each
Warrantholder agrees with the Company that the Articles (insofar as they relate to the Warrants) and the terms of this instrument shall be binding upon the Company and each Warrantholder and all persons claiming through or under either of them.

  

	2.6	 No application will be made for the Warrants to be listed or dealt on any Recognised Investment Exchange (as
that term is defined in the Financial Services and Markets Act 2000 (as amended)). 

  
 8 

	3	 CALCULATION OF NUMBER OF WARRANT SHARES 

The number of Warrant Shares over which Warrants will be issued at the date of this instrument (the Issue Date) shall be _______________
Warrant Shares, such Warrants to be issued to Silicon Valley Bank and Kreos Capital V (Expert Fund) LP in equal proportions. 
  

	4	 CERTIFICATES 

  

	4.1	 The Company shall issue to each Warrantholder a Warrant Certificate in respect of that number of Warrants to
which it is entitled as soon as reasonably practicable following a Warrantholder becoming entitled to such Warrants in accordance with clause 3 (Calculation of number of Warrant Shares). 

 

	4.2	 If a Warrant Certificate is mutilated, defaced, lost, stolen or destroyed, the Company will replace it on such
terms as to evidence and indemnity as the Company may reasonably require and subject to the Warrantholder who is seeking the replacement paying the Company’s reasonable costs (if any) in connection with the issue of the replacement.

  

	4.3	 Mutilated or defaced Warrant Certificates must be surrendered before replacements will be issued.

  

	5	 TIMING FOR EXERCISE OF SUBSCRIPTION RIGHTS 

 

	5.1	 The Subscription Rights may be exercised at any time from the date of this instrument until 17:00 GMT on the
Final Date and shall be exercised in accordance with clause 6 (Exercise of Subscription Rights). 

  

	5.2	 Subject to clause 7 (Automatic Exercise of Subscription Rights), a failure by any Warrantholder to
exercise its Subscription Rights ahead of such time on the Final Date shall mean that such Warrantholder’s outstanding Warrants shall immediately lapse and be cancelled and such Warrantholder shall have no further rights under this instrument.

  

	5.3	 Without prejudice to clauses 12 (Liquidation), 13 (Takeovers) and 14 (Company reorganisations
– Exchange of Warrants), if the Final Date is likely to occur before the last date for approval of or acceptance of a liquidation, share buyback, takeover or reorganisation event (that is in each case subject to an existing proposal) such
as described in the said clauses, the Final Date shall be extended until such last date for approval or acceptance of such event as aforesaid. 

  

	6	 EXERCISE OF SUBSCRIPTION RIGHTS 

 

	6.1	 The Subscription Rights may be exercised in whole or in part. If exercised in part, the Subscription Rights
must be exercised in tranches of 50,000 Warrants, or in respect of the last tranche of Warrants attached to the outstanding Subscription Rights held by the Warrantholder concerned, such lesser balancing number of Warrants as may be outstanding.

  
 9 

	6.2	 In order to exercise its Subscription Rights validly, a Warrantholder must deliver the following items to the
registered office of the Company: 

  

	 	6.2.1	 the Warrant Certificate for the Warrants in respect of which Subscription Rights are being exercised, together
with the Notice of Subscription duly completed; 

  

	 	6.2.2	 if required pursuant to clause 6.3.1, a remittance by banker’s draft, drawn on a UK clearing bank, (or
such other mode of payment as the Company and the Warrantholder shall agree); and 

  

	 	6.2.3	 the name and address of the Warrantholder to which the Warrant Shares arising on exercise of Subscription
Rights are to be issued. 

  

	6.3	 The Subscription Price for each of the Warrant Shares shall, at the absolute discretion of the Warrantholder,
be satisfied by any of the following: 

  

	 	6.3.1	 the payment by banker’s draft for each of the Warrant Shares at the Subscription Price; or

  

	 	6.3.2	 in lieu of cash payment in respect of the aggregate Subscription Price for the Warrant Shares, the
Warrantholder may elect to receive a reduced number of Warrant Shares (as calculated below) (Reduced Warrant Shares) than the number to which it would be entitled on exercise of the Subscription Right in full, payment for such Reduced Warrant
Shares being satisfied by waiver by the Warrantholder of the right to receive the balance of Warrant Shares to which the Warrantholder is entitled over and above the Reduced Warrant Shares (Balance Warrant Shares). In doing so, the Company
agrees and acknowledges that, subject to the payment of the par value of the Reduced Warrant Shares pursuant to this clause 6.3.2, the Reduced Warrant Shares to be issued to the Warrantholder shall be issued as fully paid up at the Subscription
Price and the Warrantholder agrees and acknowledges that it waives its Subscription Rights to the Balance Warrant Shares used as consideration for the payment of the aggregate Subscription Price. The number of Reduced Warrant Shares the
Warrantholder will receive shall be determined as follows: 

  

	
	X = Y (A-B)/A

 where: 

X = the number of Reduced Warrant Shares to be issued to the Warrantholder. 

Y = the number of Warrant Shares with respect to which the Warrant is being exercised by the Warrantholder (without application of the
reduction). 
 A = the Fair Market Value of one Warrant Share 

B = the Subscription Price. 

  
 10 

 Provided always that the Warrantholder shall nevertheless be required to subscribe in cash
for the par value of the Reduced Warrant Shares to the extent that if it did not do so the Reduced Warrant Shares would be issued at a discount to the Warrantholder. It being understood that if Warrant Shares are issued pursuant to this clause
6.3.2, notwithstanding that such Warrant Shares are issued at nominal value, the Warrantholder shall be deemed to have paid the relevant Subscription Price per Warrant Share for the purposes of calculating any distribution or share of sale proceeds
in each case attributable to the Warrant Shares and to other issued shares of the class for the purposes of the Articles and for all other purposes. 
  

	6.4	 Delivery of the items specified in clause 6.2 to the Company shall, unless the Company expressly consents
otherwise, be an irrevocable election by the Warrantholder to exercise the relevant Subscription Rights. 

  

	7	 AUTOMATIC EXERCISE OF SUBSCRIPTION RIGHTS 

 

	7.1	 If, on the Final Date, the Fair Market Value of one Warrant Share is greater than the Subscription Price on
such date, the Warrantholder shall be deemed to have automatically exercised its Subscription Rights, on a conditional basis, in respect of all unexercised Warrants on such date on a net issuance basis as set out in clause 6.3.2 (Exercise of
Subscription Rights). In such circumstances, the Company shall (subject at all times to the Company’s obligations under the Takeover Code, the AIM Rules, and all applicable law and any other regulations including the Market Abuse
Regulation), send a notice to the Warrantholder(s) within ten (10) Business Days of the Final Date (such notice being the “Automatic Exercise Notice” for the purposes of this clause 7) requiring them to pay up a cash amount
equal to the aggregate nominal value of the Warrant Shares (such payment being the “Nominal Value Payment”) to be issued pursuant to clause 6.3.2 (Exercise of Subscription Rights) and this clause 7.1. 

 

	7.2	 The Warrantholder shall, within ten (10) Business Days of receipt of the Automatic Exercise Notice (the
“Nominal Value Payment Period”), provide the Company with the Nominal Value Payment, to an account notified by the Company to the Warrantholder. Upon receipt of such the Nominal Value Payment, the Warrant Shares to be issued to the
Warrantholder on a net issuance basis pursuant to clause 6.3.2 (Exercise of Subscription Rights) shall be allotted and issued to the Warrantholder credited as fully paid up in accordance with clause 6.3.2 (Exercise of Subscription
Rights) and clause 8.3.1 (Completion). Any failure by a Warrantholder to pay the Nominal Value Payment within the Nominal Value Payment Period shall result in the automatic lapse of any Warrants over Warrant Shares for which the Nominal
Value Payment was not made. 

  
 11 

	8	 COMPLETION 

  

	8.1	 Following a valid exercise of Subscription Rights by a Warrantholder or an automatic exercise of Subscription
Rights pursuant to clause 7 (Automatic exercise of Subscription Rights) or clause 13.2.2 (Takeovers), the Company shall in accordance with clause 8.3: 

 

	 	8.1.1	 allot and issue credited as fully paid to the Warrantholder (or to its nominee or trustee as notified to the
Company in the Notice of Subscription) the Warrant Shares to which the Warrantholder is entitled by exercising the Subscription Rights (“Allotted Shares”); 

 

	 	8.1.2	 immediately following allotment and issue in accordance with clause 8.1.1, enter, or procure that the
Company’s Registrars enter the Warrantholder’s name (or its nominee’s or trustee’s name, as appropriate) in the register of members of the Company as the holder of the Allotted Shares; 

 

	 	8.1.3	 immediately following registration in accordance with clause 8.1.2, either send to the person identified by the
Warrantholder pursuant to clause 8.1.1, free of charge, share certificate(s) in respect of the Allotted Shares or credit such aggregate number of Allotted Shares to the Warrantholder’s (or its nominee’s or trustee’s) CREST stock
account; and 

  

	 	8.1.4	 apply for the admission of the Warrant Shares to trading on (i) AIM, insofar as the Warrant Shares are
listed on AIM or, (ii) on any other recognised investment exchange on which the Warrant Shares are listed, and shall use its reasonable endeavours to secure such admission to trading no later than ten (10) Business Days after such
application. 

  

	8.2	 The obligations of the Company under clause 8.1 shall be fulfilled within ten (10) days after the Notice
of Subscription is lodged at the registered office of the Company. 

  

	8.3	 The Allotted Shares shall: 

 

	 	8.3.1	 be allotted and issued fully paid; 

 

	 	8.3.2	 rank pari passu with the relevant class of fully paid Warrant Shares then in issue; 

 

	 	8.3.3	 rank for any dividend or other distribution which has previously been announced or declared if the date by
which the holder of Warrant Shares must be registered to participate in such dividend or other distribution is after the Exercise Date pursuant to which the Subscription Rights have been exercised; and 

 

	 	8.3.4	 be free from all claims, liens, charges, encumbrances, equities and third party rights. 

 

	8.4	 If following allotment of shares pursuant to the exercise of some of the Subscription Rights, some Subscription
Rights remain, the Company shall issue a Warrant Certificate to the Warrantholder within 15 Business Days for the balance of the Warrantholder’s Subscription Rights. 

  
 12 

	9	 TRANSFER OF WARRANTS 

 

	9.1	 Subject to clause 9.2, the Warrants may be transferred in whole or in part by any Warrantholder to any person,
provided that the Company has given its prior written consent to such transfer. 

  

	9.2	 A Warrantholder has the right, with prior written notice, but without the consent of the Company, to transfer
the Warrants in whole or in part to a Permitted Transferee, subject to compliance with the provisions of Schedule 2 hereto. 

  

	9.3	 Notwithstanding any other provisions of this instrument, no transfer shall be made to any person which is a
Competitor of the Company or any other Group Company. 

  

	9.4	 The provisions of Schedule 2 to this instrument shall regulate any transfer of a Warrant.

  

	10	 MODIFICATION AND CESSATION OF RIGHTS 

 

	10.1	 This instrument may be modified only with the prior sanction of Consent. 

 

	10.2	 This instrument ceases to have effect on the earlier of: 

 

	 	10.2.1	 the date upon which all Subscription Rights have been exercised in full; and 

 

	 	10.2.2	 the Final Date. 

  

	11	 ADJUSTMENT OF WARRANT 

 

	11.1	 Upon the occurrence of an Adjustment after the date of this Instrument but prior to the Final Date, the number
and/or nominal value of Warrant Shares to be, or capable of being subscribed on any subsequent exercise of the Subscription Rights conferred by each issued Warrant and/or the Subscription Price will be adjusted in such manner as the Auditors shall
certify to be fair and reasonable so that the Warrants shall, after such adjustment, entitle the Warrantholder(s) on exercise to receive the same percentage of the share capital of the Company in issue or capable of being issued following the
implementation of the Adjustment, carrying the same proportion of votes exercisable at a general meeting of shareholders, for the same price, in each case as nearly as practicable, as would have been the case if no Adjustment had occurred, provided
that the Subscription Price shall not in any event be reduced so that, upon exercise of the Subscription Rights, Warrant Shares would fall to be issued at a discount to their nominal value. 

 

	11.2	 Within ten (10) days after an Adjustment, notice of such adjustments will be given to the Warrantholder(s)
detailing the number of Warrant Shares for which the Warrantholder(s) are entitled to subscribe in consequence of any such adjustment. Replacement Warrant Certificates shall be issued accordingly. 

  
 13 

	12	 LIQUIDATION 

  

	12.1	 If an order is made or an effective resolution is passed for the
winding-up or dissolution of the Company or if any other dissolution of the Company by operation of law is to be effected whilst any Subscription Rights remain exercisable, then the provisions of clause 12.2
or, as the case may be, clause 12.3 shall apply. 

  

	12.2	 If the winding-up or dissolution is for the purpose of a
reconstruction, amalgamation or merger the Warrantholder shall be entitled to be granted by the reconstructed, amalgamated or merged company a substituted warrant of the value of the Warrant immediately prior to such reconstruction, amalgamation or
merger. 

  

	12.3	 If clause 12.2 does not apply, the Company shall immediately notify the Warrantholder(s) in writing that such
an order has been made or resolution has been passed or other dissolution is to be effected. The Warrantholder(s) shall be entitled at any time within three (3) months after the date such notice is given to elect by notice in writing to the
Company to be treated as if they had, immediately before the date of the making of the order or passing of the resolution or other dissolution, exercised the Subscription Rights and they shall be entitled to receive out of the assets which would
otherwise be available in the liquidation to the holders of Warrant Shares, such a sum, if any, as they would have received had they been the holders of and paid for the Warrant Shares to which they would have become entitled by virtue of such
exercise, after deducting from such sum the amount which would have been payable by them in respect of the Warrant Shares if they had exercised the Subscription Rights. Nothing contained in this clause 12.3 shall have the effect of requiring the
Warrantholder(s) to make any actual payment to the Company. 

  

	13	 TAKEOVERS 

  

	13.1	 Subject to clause 13.6, if at any time an offer or invitation is made by the Company to the holders of the
Ordinary Shares for the purchase by the Company of any of its Ordinary Shares, the Company shall promptly and without delay give notice thereof to each Warrantholder who shall be entitled, at any time whilst such offer or invitation is open for
acceptance, to exercise its Subscription Rights to the extent that such rights have not been exercised or lapsed prior to the record date of such offer or invitation so as to take effect, in so far as is reasonably practicable, as if it had
exercised its rights immediately prior to the record date of such offer or invitation. 

  

	13.2	 Subject to clause 13.6, if at any time an offer is made to all holders of Ordinary Shares (or all holders of
Ordinary Shares other than the offeror and/or any company controlled by the offeror and/or persons acting in concert with the offeror) to acquire the whole or any part of the issued share capital of the Company and the Company becomes aware that as
a result of such offer the right to cast a majority of the votes which may ordinarily be cast on a poll at a general meeting of the Company may, if such offer becomes unconditional in all respects, become vested in the offeror and/or such persons or
companies (the “Buyer”) as aforesaid (the “Offer”): 

  
 14 

	 	13.2.1	 The Company shall, subject to compliance with the Takeover Code, give notice to each Warrantholder within ten
(10) Business Days of its becoming so aware, and each Warrantholder shall be entitled to exercise its Subscription Rights, conditional upon the Offer being declared unconditional in all respects, within thirty (30) days of such notice
having been given by the Company (to the extent that such rights have not lapsed or been exercised prior to the record date of such Offer), and to accept or otherwise participate in such Offer on the same terms as made to all holders of Ordinary
Shares. 

  

	 	13.2.2	 If the Company fails to give notice as required by clause 13.2.1 (subject at all times to the Company’s
obligations under the Takeover Code, the AIM Rules, and all applicable law and any other regulations including the Market Abuse Regulation) then, provided that immediately prior to the date that the Offer is made the offer price under the Offer is
greater than the Subscription Price on such date and conditional upon the Offer being declared unconditional in all respects, the Warrantholder shall be deemed to have automatically exercised its Subscription Rights in respect of all unexercised
Warrants on such date at the Subscription Price on a net issuance basis as set out in clause 6.3.2(Exercise of Subscription Rights). In such circumstances, the Company shall send a notice to the Warrantholder(s) promptly and without delay
(such notice being the “Exercise Notice” for the purposes of this clause 13.2.2) upon either a Warrantholder notifying the Company of its failure to give notice as required by clause 13.2.1 or the Company or the Buyer becoming aware
of the Company’s failure to give such notice requiring the Warrantholder(s) to pay the Nominal Value Payment. The Warrantholder shall, within ten (10) Business Days of receipt of the Exercise Notice, provide the Company with the Nominal
Value Payment, to an account notified by the Company to the Warrantholder. Upon receipt of such the Nominal Value Payment, subject to clause 13.3 the Warrant Shares to be issued to the Warrantholder on a net issuance basis pursuant to clause 6.3.2
(Exercise of Subscription Rights) shall be allotted and issued to the Warrantholder credited as fully paid up in accordance with clause 6.3.2 (Exercise of Subscription Rights) and clause 8.3.1. 

 

	 	13.2.3	 Nothing in this clause 13.2 shall oblige the Warrantholder(s) to accept any Offer made hereunder, save to the
extent that such Offer, whether by court order or otherwise, shall have become binding on all shareholders and the offer price under such Offer is greater than the Subscription Price, in which case the Warrantholder(s) shall be deemed to have
accepted it on the terms set out herein. 

  

	13.3	 The Company undertakes to the Warrantholders that in the event of an exercise of Subscription Rights during the
course of an Offer (or before the date of an Offer if the Directors of the Company have reason to believe that a bona fide offer might be imminent) it will consult with the Panel on Takeover and Mergers without delay to get

  
 15 

	 	
confirmation that the issue of shares represents the exercise of the Subscription Rights pursuant to a pre-existing contractual obligation. In the event
that the Panel of Takeover and Mergers does not give such confirmation, the Company will undertake without delay to call a general meeting of the Company to approve the issue of shares pursuant to the Subscription Rights. 

 

	13.4	 The Company shall use reasonable endeavours to procure that any Buyer extends the Offer to the Warrantholders
in accordance with Rule 15 and Practice Statement 24 of the Takeover Code. 

  

	13.5	 For the avoidance of doubt, publication of a compromise or scheme of arrangement under the Companies Act
providing for the acquisition by any person of the whole or any part of the issued share capital of the Company shall be deemed to be the making of an Offer for the purposes of this clause 13. 

 

	13.6	 If, for whatever reason, a Warrantholder fails, refuses or declines to exercise its Subscription Rights within
sixty (60) days of an Offer having become unconditional in all respects, the Warrants held by such Warrantor shall automatically lapse and no Warrant Shares shall be issued to the Warrantholder thereunder. 

 

	14	 COMPANY REORGANISATIONS – EXCHANGE OF WARRANTS 

 

	14.1	 A company reorganisation occurs if the Company merges with or transfers all or substantially all of its assets
and undertaking to a new company (“Newco”) and the shareholders of Newco are substantially the same as the shareholders of the Company immediately before the Company reorganisation, with shares having the same rights as those of the
Company. 

  

	14.2	 If there is a company reorganisation, the Company shall, save to the extent proposed by the Company and
sanctioned by a Consent, use reasonable endeavours to procure that new warrants over the share capital of the Newco are granted with equivalent rights and on terms applying in this instrument mutatis mutandis and on such grant the existing Warrants
shall lapse. 

  

	15	 INFORMATION AND RIGHTS OF WARRANTHOLDER(S) 

 

	15.1	 The Company shall: 

  

	 	15.1.1	 send to each Warrantholder a copy of its annual reports and audited accounts together with all documents
required by law to be annexed to that report at the same time they are provided to the holders of the Ordinary Shares; 

  

	 	15.1.2	 send to each Warrantholder copies of any statements, notices or circulars sent to the holders of the Ordinary
Shares; and 

  

	 	15.1.3	 give to each Warrantholder not less than 30 days’ prior written notice of its intention to declare or pay
a dividend or other distribution on the Ordinary Shares. 

  
 16 

	15.2	 The Warrantholder(s) may attend all general meetings of members of the Company and meetings of the holders of
Ordinary Shares but may not vote at those meetings by virtue of or in respect of their holdings of Warrants. 

  

	15.3	 Each Warrantholder shall keep confidential any information received by it in its capacity as a Warrantholder
which is of a confidential nature except: 

  

	 	15.3.1	 as required by law or any applicable regulations; 

 

	 	15.3.2	 to the extent the information is in the public domain through no default of the Warrantholder; and

  

	 	15.3.3	 each Warrantholder will be entitled to divulge such information to any other Warrantholder and any proposed
transferee of Warrants on the same terms as to confidentiality. 

  

	16	 RESTRICTIONS ON AND UNDERTAKINGS OF THE COMPANY 

 

	16.1	 For so long as the Warrants are outstanding, the Company will: 

 

	 	16.1.1	 to the extent that the Company has a limit on its authorised share capital, keep available for issue and free
from pre-emptive rights, out of its authorised but unissued share capital, such number of Warrant Shares as will enable the Subscription Rights of the Warrantholder(s) to be satisfied in full;

  

	 	16.1.2	 ensure that the Directors have all necessary authorisations and disapplications of pre-emption (including under the Companies Act) to allot such number of Warrant Shares as will enable the Subscription Rights of the Warrantholder(s) to be satisfied in full at any time; 

 

	 	16.1.3	 maintain the admission to trading of the Ordinary Shares on AIM, or any other Recognised Investment Exchange on
which the Ordinary Shares are traded from time to time; 

  

	 	16.1.4	 not make any issue, grant or distribution or take any other action the effect of which would be that on
exercise of any of the Subscription Rights it would be required to issue Warrant Shares at a discount to their nominal value; and 

  

	 	16.1.5	 not buy any Warrants unless it offers to buy Warrants from all Warrantholders in proportion to their respective
holdings of Warrants. 

  

	17	 WARRANTIES 

  

	17.1	 The Company warrants to the Warrantholder(s) that: 

 

	 	17.1.1	 it has the power to execute and to perform its obligations under this instrument; 

  
 17 

	 	17.1.2	 it has taken all action necessary to authorise the execution of, and the performance of its obligations under
this instrument; 

  

	 	17.1.3	 all Warrant Shares which may be issued upon the exercise of the rights represented by this Warrant will be,
upon issuance, be duly authorised, validly issued and fully paid and free of any liens and encumbrances; 

  

	 	17.1.4	 it and the Directors have, and have obtained all necessary shareholder and third party consents (which consents
are subsisting and remain sufficient and have not been revoked at the Issue Date), to grant the Warrant to the Warrantholder(s) on the Issue Date on the terms of this Warrant; and 

 

	 	17.1.5	 the Ordinary Shares are duly admitted to trading on AIM or on another Recognised Investment Exchange and no
circumstances exist which may cause the suspension or cancellation of such admission. 

  

	18	 NOTICES 

Any notice to the Warrantholder(s) required for the purposes of any provision of this instrument shall be given in accordance with the
provisions of paragraphs 10 to 13 (inclusive) of Schedule 2. 
  

	19	 COSTS AND EXPENSES 

 

	19.1	 The Company shall promptly pay to the Warrantholder(s) on the Warrantholder’s demand, the reasonable legal
expenses plus applicable VAT and disbursements incurred by the Warrantholder in connection with: 

  

	 	19.1.1	 any amendment or supplement to this instrument, or any proposal for such an amendment to be made, provided such
amendment or supplement has been requested or necessitated by the Company; and 

  

	 	19.1.2	 any consent or waiver by the Warrantholder(s) concerned under or in connection with this instrument or any
request for such a consent or waiver, provided that such consent or waiver has been requested or necessitated by the Company; and 

  

	 	19.1.3	 any step taken reasonably and properly by the Warrantholder with a view to the protection, exercise or
enforcement of any right or interest created by this instrument. 

  

	20	 CONTRACTS (RIGHTS OF THIRD PARTIES) ACT 1999 

A person who is not a party to this instrument shall have no rights under the Contracts (Rights of Third Parties) Act 1999 to enforce any term
of this instrument. This clause does not affect any right or remedy of any person which exists or is available otherwise than pursuant to that Act. 

  
 18 

	21	 FURTHER ASSURANCE  

The Company shall, at its own cost and expense, execute all such deeds and documents and do all such acts and things as may reasonably be
required in order to give effect to this instrument, including vesting on issue the full legal and beneficial title to the Warrant Shares in the Warrantholder. 
  

	22	 SEVERABILITY  

Each of the provisions of this instrument is distinct and severable from the others and if at any time one or more of such provisions is or
becomes valid, unlawful or unenforceable (whether wholly or to any extent), the validity, lawfulness and enforceability of the remaining provisions (or the same provision to any other extent) of this instrument shall not in any way be affected or
impaired. 
  

	23	 GOVERNING LAW  

The provisions of this instrument and the Conditions and any dispute or claim arising out of or in connection with them (including any dispute
or claim relating to non-contractual obligations) shall be subject to and governed by English law and the Company and the Warrantholder(s) submit to the exclusive jurisdiction of the English Courts in relation
to any such dispute or claim. 
 The Company intends this instrument to be a deed poll and accordingly it or its duly authorised representatives execute and
deliver it as such. 

  
 19 

 SCHEDULE 1 

Form Of Warrant Certificate 

MEREO BIOPHARMA GROUP PLC (“COMPANY”) 

A company registered in England and Wales 

under Company number 09481161 

WARRANT CERTIFICATE 
 This certificate is
issued pursuant to the warrant instrument issued by the Company on                      2018 (“Warrant Instrument”). Words
and expressions used in this certificate which are defined in the Warrant Instrument have the meanings given to them in the Warrant Instrument. 
  

			
	Certificate number:	 	[●]
		
	Date of issue:	 	                     2018
		
	Name and address of Warrantholder:	 	[Silicon Valley Bank of 3003 Tasman Drive, Santa Clara, California 95054 US (UK branch at Alphabeta 14-18 Finsbury Square, London EC2A 1BR)]
		
		 	[Kreos Capital V (Expert Fund) LP of 47 Esplanade, St. Helier, Jersey JE1 0BD]

 Number of Warrant Shares for which the Warrantholder may subscribe such number as is [number], as adjusted in accordance with
terms of the Warrant Instrument, if appropriate. 
 This is to certify that the Warrantholder named above is the registered holder of the right to subscribe
in cash for Warrant Shares at the subscription price set out above subject to the Articles and otherwise on the terms and conditions set out in the Warrant Instrument (a copy of which is available for inspection at the registered office of the
Company). 
  

					
	 EXECUTED as a deed, but not delivered until)

the date specified on this certificate, by             )

MEREO BIOPHARMA GROUP PLC          )

by
                                         
     a director in the)
 presence of a witness:
	 		 	  

		 		 	  
 Director

  

			
	 Witness Signature:
	  	  

		
	 Witness Name (block capitals):
	  	  

		
	 Witness Address:
	  	  

		
		  	  

		
	 Witness Occupation:
	  	  

  
 20 

 Schedule to the Warrant Certificate 

Notice of Subscription 
  

	To:	 The Directors 

MEREO BIOPHARMA GROUP PLC (“Company”) 

This notice is issued pursuant to the warrant instrument issued by the Company on
                         2018 (“Warrant Instrument”). Words and expressions used in this notice which are
defined in the Warrant Instrument have the meanings given to them in the Warrant Instrument. 
 By this notice we exercise the Subscription Rights
appertaining to [all] [number] of the Warrants evidenced by this certificate. 
 We wish to satisfy the aggregate Subscription Price for the Warrant
Shares in respect of the Subscription Rights we are exercising as follows [delete options as necessary]: 
  

	1	 [by payment by banker’s draft, we attach a banker’s draft to this notice]; 

 

	2	 [by satisfying the aggregate Subscription Price by electing to receive a reduced number of Warrant Shares, in
accordance with clause 6.3.2 (Exercise of Subscription Rights)]. 

 [We direct the Company to allot conditional only on the
above the [number] of Ordinary Shares to be issued pursuant to this exercise in the following numbers to the following proposed allottees, each of which is either a Warrantholder, a nominee or trustee of a Warrantholder, or a transferee of
one of those persons approved in accordance with clause 9.1 of the Warrant Instrument.] 
  

							
	 Number/percentage of shares
	  	 Name of proposed allottee
	  	 Address of proposed allottee
	  	 CREST Details

	1	  		  		  	Participant ID: [●]
		  		  		  	Member account ID: [●]
		  		  		  	INSP Custodian Client Ref: [●]
		  		  		  	Custodian Name: [●]
				
	2	  		  		  	Participant ID: [●]
		  		  		  	Member account ID: [●]
		  		  		  	INSP Custodian Client Ref: [●]
		  		  		  	Custodian Name: [●]

  
 21 

 We request that certificate(s) for such Ordinary Shares be sent by post at our risk to us at the first
address shown above or to the agent lodging this certificate as mentioned below. 
 OR 

We hereby request that you register our Warrant Shares in uncertificated form to the CREST account detailed [below][above]: 

 

			
	CREST Details	  	 Participant ID
  

Member Account ID
  

INSP Custodian Client Ref:
  

Custodian Name

 We agree that such shares are issued and accepted subject to the memorandum and articles of association of the Company. 

 

			
	Signature of Warrantholder:	 	 
		
	Full name:	 	 
		
	Address:	 	 
	
	Lodged by: (agent to whom certificate(s) should be sent)
		
	Name of agent:	 	 
		
	Address:	 	 

  
 22 

 SCHEDULE 2 

Conditions 
  

	1	 An accurate Register will be kept and maintained at all times by the Company at its registered office and there
shall be entered in the Register: 

  

	1.1	 the names and addresses of the persons for the time being entitled to be registered as the holders of the
Warrants; 

  

	1.2	 the number of Warrants held for the time being by every registered holder; and 

 

	1.3	 the date on which the name of every registered holder is entered in the Register in respect of the Warrants in
its name. 

  

	2	 Any change in the name or address of any Warrantholder shall promptly be notified to the Company which shall
cause the Register to be altered accordingly. The Warrantholders or any of them and any person authorised by any Warrantholder shall be at liberty at all reasonable times during office hours to inspect the Register and to take copies of or extracts
from it or any part of it. 

  

	3	 The Company shall be entitled to treat each Warrantholder as the absolute owner of a Warrant and accordingly
shall not, except as ordered by a court of competent jurisdiction or as required by law, be bound to recognise any equitable or other claim to or interest in a Warrant on the part of any other person, whether or not it shall have express or other
notice of such a claim. 

  

	4	 Each Warrantholder will be recognised by the Company as entitled to the Warrants free from any equity, set-off or cross-claim on the part of the Company against the original or any intermediate holder of the Warrants. 

  

	5	 Each transfer of a Warrant shall be made by an instrument of transfer in the usual or common form or in any
other form which may be approved for the time being by the Directors. 

  

	6	 The instrument of transfer of a Warrant shall be executed by or on behalf of the transferor but need not be
executed by or on behalf of the transferee. The transferor shall be deemed to remain the holder of the Warrant until the name of the transferee is entered in the Register in respect of the Warrant being transferred. 

 

	7	 The Directors may decline to recognise any instrument of transfer of a Warrant unless the instrument is
deposited at the registered office of the Company accompanied by the Warrant Certificate for the Warrant to which it relates, and such other evidence as the Directors may reasonably require to show the right of the transferor to make the transfer.
The Directors may waive production of any Warrant Certificate upon production to them of satisfactory evidence of the loss or destruction of the Warrant Certificate together with such indemnity as they may require. 

  
 23 

	8	 No fee shall be charged for any registration of a transfer of a Warrant or for the registration of any other
documents which in the opinion of the Directors require registration. 

  

	9	 The registration of a transfer shall be conclusive evidence of the approval by the Directors of such a
transfer. 

  

	10	 Each Warrantholder shall register with the Company an address in the United Kingdom to which notices can be
sent. If any Warrantholder fails to register an address with the Company, notice may be given to that Warrantholder by sending it by any of the methods referred to in paragraph 11 of this Schedule 2 to that Warrantholder’s last known place of
business or residence or, if none, by exhibiting it for three days at the registered office for the time being of the Company. 

  

	11	 Notices and other communications to Warrantholders may be given by personal delivery, prepaid letter by first
class post or, subject to clause 1.3 of this instrument, fax or email. In proving service of any notice or other communication sent by post, it shall be sufficient to prove that the envelope containing the notice or other communication was properly
addressed and stamped and was deposited in a post box or at the post office. 

  

	12	 A notice or other communication given pursuant to the provisions of paragraph 11 of this Schedule 2 shall be
deemed to have been served: 

  

	12.1	 at the time of delivery, if delivered personally to the registered address; 

 

	12.2	 on the second Business Day following its posting, if sent by prepaid letter by first class post to an address
in the United Kingdom; and 

  

	12.3	 at 09:00 hours on the Business Day following the despatch of the fax, if sent by fax. 

 

	13	 All notices and other communications with respect to Warrants standing in the names of joint registered holders
shall be given to whichever of such persons is named first in the Register and such notice so given shall be sufficient notice to all the registered holders of such Warrants. 

 

	14	 Any person who, whether by operation of law, transfer or other means whatsoever, shall become entitled to any
Warrant, shall be bound by every notice in respect of such Warrant which, prior to its name and address being entered on the Register, shall have been duly given to the person from which it derives its title to such Warrant. 

 

	15	 When a given number of days’ notice or notice extending over any other period is required to be given, the
day of service shall be included but the day upon which such notice will expire shall not be included in such number of days or other period. The signature to any notice to be given by the Company may be written or printed. 

 

	16	 Meetings of Warrantholders shall be convened and conducted in the same way as meeting of shareholders of the
Company are convened and conducted. Accordingly, the provisions of Articles shall apply to meetings of the Warrantholders mutatis mutandis. 

  
 24 

 SIGNATURE PAGE 

 

			
	 EXECUTED as a deed, but not delivered until)
	  	
	 the date specified on this instrument, by
          )
	  	
	                          )	  	 
	 MEREO BIOPHARMA GROUP PLC         )
	  	
		
	 by
                                         
    a director in the
	  	
	 presence of a witness:
	  	  

		  	 Director

		
	 Witness Signature:
	  	  

		
	 Witness Name (block capitals):
	  	  

		
	 Witness Address:
	  	  

		
		  	  

		
	 Witness Occupation:
	  	  

  
 25

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00291-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00291-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00291-of-00352.parquet"}]]